THE JOURNAL OF BIOLOGICAL CHEMISTRY 0 1986 by The American Society of Biological Chemists, Inc

Vol. 261, No. 32, Issue of November 15, pp. 15310-15315,1986 Printed in U. S. A.

Isolation and Characterization of a Collagen Binding Domain in Human von Willebrand Factor*

(Received for publication, May 16, 1986)

Francesco I. Pareti*, Yoshihiro Fujimura, Judith A. Dent, Linda Z. Holland, Theodore S. Zimmerman, and Zaverio M. Ruggerie From the Department of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolln, California 92037

von Willebrand factor binds to fibrillar type I colla- gen in a rapid, temperature-independent, reversible, specific, and saturable manner. Evaluation of binding isotherms by Scatchard-type analysis demonstrated that 6-18 pg of von Willebrand factor bind per mg of collagen, with K, between 2 and 8 X los M-’. Five distinct tryptic fragments, purified under denaturing and reducing conditions and representing over 75% of the molecular mass of the von Willebrand factor sub- unit, were tested for their capacity to inhibit the von Willebrand factor-collagen interaction. Complete in- hibition was obtained with a 52/48-kDa fragment at a concentration of -1 p ~ . The location of this fragment in the subunit was established to be between Val-449 and Lys-728. Fifteen monoclonal antibodies against the 52/48-kDa fragment inhibited von Willebrand fac- tor binding to collagen. Six antibodies against other portions of the von Willebrand factor subunit had no inhibitory effect. The tryptic fragment was a compet- itive inhibitor of von Willebrand factor binding to collagen and, therefore, recognizes the same interac- tion site as the intact molecule. These studies precisely define a domain in the von Willebrand factor subunit that interacts with type I collagen.

von Willebrand factor (vWF’) plays an essential role in primary hemostasis as one of the adhesive proteins that mediate platelet plug formation a t sites of vascular injury (1- 4). Its activity is expressed through the interaction with receptors on the platelet surface (5-7) as well as with com- ponents of the vessel wall (4, 8-11). Thus, vWF acts as an essential anchoring molecule that initiates platelet deposition at the wound site. The physiological importance of this func- tion is demonstrated by the fact that platelet adhesion to exposed subendothelium is severely impaired in patients with von Willebrand disease, who lack vWF (1-3).

* This work was supported in part by Grants HL 31950 and HL 15491 from the National Institutes of Health and by United States Public Health Service Grant RR 00833. This is Publication 4368 BCR from the Research Institute of Scripps Clinic, La Jolla, CA 92037. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ‘‘aduertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

$Partially supported by a grant from Fondazione Anna Villa Rusconi, Varese, Italy.

5 To whom correspondence should be addressed; Scripps Clinic and Research Foundation (BCR 8), 10666 N. Torrey Pines Rd., La Jolla, CA 92037. ’ The abbreviations used are: vWF, von Willebrand factor; GP, platelet membrane glycoprotein; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; HPLC, high-pressure liquid chro- matography.

A significant amount of experimental work, performed over the past several years, has led to the demonstration that vWF binds to both collagen and noncollagenous components of the vessel wall (12-21). More recent studies have attempted to define the structural basis for the interaction with collagen and have provided preliminary information on discrete frag- ments of vWF that appear to subserve this function (22-24).

In this report we describe the isolation and characterization of a high affinity collagen binding domain of human vWF. By using a combination of different techniques, including limited proteolysis, partial NH,-terminal sequence analysis of proteo- lytic fragments, immunoinhibition, and direct inhibition bind- ing studies, we demonstrate here that this functional domain of vWF resides in a 52/48-kDa tryptic fragment of the con- stituent subunit that begins at amino acid residue Val-449 and extends through Lys-728. This is the same fragment of vWF that contains the binding domain for the platelet mem- brane glycoprotein (GP) Ib, as recently demonstrated (25).

MATERIALS AND METHODS

Purification of uWF-Purified vWF for trypsin cleavage studies was obtained from commercial factor VI11 concentrate (the generous gift of Armour) by immunoadsorbent chromatography followed by high-pressure liquid chromatography (HPLC), as recently described in detail (25). Purified vWF for binding studies was isolated from cryoprecipitate (the generous gift of American Red Cross, Betbesda, MD) following a procedure previously described (7). The latter ma- terial had multimeric structure and ristocetin cofactor activity com- parable to vWF in plasma, as demonstrated in previous publications (7, 26).

Preparation and Characterization of Monoclonal Antibodies against u WF-The methodology involved in establishing murine hybridoma cultures producing antibodies against vWF has been previously re- ported (27). Three different immunogens were used, namely intact vWF reduced and S-carboxymethylated vWF; and the isolated tryptic fragment, 52/48 kDa in size, described in this report as containing the collagen binding domain of vWF. The reactivity of all monoclonal antibodies was tested against each of the immunogens described above using a solid-phase enzyme-linked immunoassay (27). Moreover, the epitope specificity of the 21 antibodies used in these studies was established by a dot blotting procedure, using either purified frag- ments obtained by trypsin digestion of vWF (see below) or the cyanogen bromide fragments comprising the entire vWF subunit (28). These latter fragments were supplied by Dr. K. Titani (Department of Biochemistry, University of Washington, Seattle, WA). The dot blotting procedure was performed using 0.1-Fm pore nitrocellulose paper (pH 79, Schleicher and Schuell). The paper was first soaked in phosphate-buffered saline (0.01 M mono- and disodium phosphate, 0.14 M NaCl, 0.02% NaN3, pH 7.4) and air dried, and then 1 to 2 4 drops of the fragments tested were applied and dried in the air. The paper was subsequently treated with the “Blotto” solution described by Johnson et al. (29) in order to saturate unreacted binding sites. After this, the paper was soaked in a suitable dilution of the mono- clonal antibody being tested for 4 b, then washed with buffer, and soaked overnight in a solution of lZ5I-labeled rabbit anti-mouse IgG. Both incubations were at 22-25 “C. After extensive washing with buffer and “Blotto,” the paper was finally dried and an autoradiogram

15310

uon Willebrand Factor-Collagen Interaction 15311

obtained at -70 "C with a Kodak XRP-1 film using a Cronex Light- ning Plus screen (Du Pont). Purified I g G of the monoclonal antibodies was prepared from ascitic fluid by chromatography on DEAE-Affi- Gel blue (Bio-Rad) following a method previously published (30).

Trypsin Cleavage and Separation of Fragments-The methods used have been recently reported in detail (25). Trypsin digestion was performed by mixing 1 mg of vWF with 2500 units of enzyme (bovine pancreatic Type I; 15,000 units/mg; Sigma) and incubating for 2 h at 37 "C, pH 7.0. The fragments generated were separated by HPLC size exclusion chromatography in three main fractions (denominated A, B, and C) as previously described (25). Isolation of the 52/48-kDa doublet, mainly contained in fraction B, as well as of other fragments of 13, 22, 41 (all from fraction B), and 55 kDa (from fraction C) was performed by HPLC chromatofocusing, salt gradient elution, and size exclusion chromatography, all in the presence of 6 M urea, as recently reported (25). Reduction and S-carboxymethylation of proteins was achieved by treatment with dithiothreitol, in equal amount (w/w) to protein, for 1 h at 37 "C, followed by treatment with a 2.7-fold excess (w/w) of iodoacetamide for 30 min at room temperature (22-25 "C) and in the dark. All samples were finally dialyzed extensively against a buffer composed of 0.05 M Tris, 0.15 M NaCl, pH 7.35, concentrated by ultrafiltration (Amicon) and dialyzed again before storage at -70 "C. The tryptic fragments of vWF were analyzed by polyacryl- amide gel electrophoresis (PAGE) in the presence of sodium dodecyl sulfate (SDS) using 5-15 or 10-15% linear gradient gels under reduc- ing and nonreducing conditions (31). The gels were stained with Coomassie Brilliant Blue R (Bio-Rad). NHz-terminal sequence anal- ysis of each of the purified fragments was performed using a gas- phase sequenator (model 470A, Applied Biosystems). Identification of the phenylthiohydantoins was achieved by reverse-phase chroma- tography in an HPLC system (Perkin-Elmer) using a Zorbax phen- ylthiohydantoin column (Du Pont) following the manufacturer's in- structions.

Binding of u WF to Collagen-vWF for these studies was radiola- beled with Iz5I following the technique described by Fraker and Speck (32) using IODO-GEN (Pierce Chemical Co.). The radiolabeled lZ5I- vWF retained its native multimeric structure, as previously described in detail (7, 26). The specific activity of the preparations used in these studies varied between 2.46 and 8.55 X 10" Ci/mg (or 9.13- 31.7 X lo6 Bq/mg). The collagen preparation used was obtained commercially (Hormon-Chemie, Munich, Federal Republic of Ger- many) and consisted of an acid-insoluble microfibrillar equine colla- gen derived from tendons. Purity analysis and physicochemical char- acterization of the fibrillar collagen suspension was made difficult by the fact that the preparation was insoluble in SDS. That fraction that was soluble in SDS was shown to be free of noncollagenous proteins by PAGE (5 or 7.5% acrylamide with 5% cross-linking) in conjunction with Coomassie Brilliant Blue R staining. The fact that the collagen fibrils were insoluble in acid and SDS indicated that they were covalently cross-linked. Differential scanning calorimetry of the fibrillar collagen preparation (kindly provided by Dr. John McPherson, Collagen Corporation, Palo Alto, CA) provided addi- tional evidence for a low degree of covalent cross-linking.

Each binding mixture contained 12.5 pl of the collagen suspension (1 mg/ml in isotonic glucose solution, pH 2.7), 5 pl of 0.4 M phosphate buffer (mono- and disodium), pH 7, and a volume of 132.5 pl which comprised the appropriate concentration of Iz5I-vWF as well as other test reagents, when necessary, all in 0.02 M Tris, 0.15 M NaCl buffer, pH 7.4. The mixture also contained 0.48% bovine serum albumin (Fraction V, Calbiochem). Incubation was usually at room tempera- ture (22-25 'C) for 20 min, except when indicated otherwise. At the end of the incubation period, a 50-pl aliquot of each experimental mixture was layered in duplicate over 300 pl of 20% sucrose in the above-mentioned Tris buffer containing albumin. Separation of bound from free ligand was achieved by centrifugation for 8 min at 12,000 X g, a condition that resulted in pelleting of the insoluble collagen microfibrils while the soluble vWF remained on top of the sucrose layer. The tip of the microcentrifuge tube containing the collagen pellet was then amputated, and the associated radioactivity was quantitated in a multichannel y scintillation spectrometer (Pack- ard Instrument Co.). The radioactivity pelleted from a mixture con- taining no collagen was subtracted from each corresponding experi- mental point. Nonsaturable (nonspecific) binding was determined by adding an excess amount of unlabeled vWF into the experimental mixture. Moreover, when binding isotherms were evaluated by Scat- chard-type analysis, nonsaturable binding was generated as a fitted parameter from the total binding isotherm using the microcomputer- assisted program LIGAND (33).

Inhibition Binding Studies-These experiments were designed to evaluate the effect of monoclonal anti-vWF antibodies and tryptic fragments of vWF on the binding of intact Iz5I-vWF to collagen. A purified IgG fraction of the monoclonal antibodies was used in these studies. The experimental mixtures were prepared as described in the preceding paragraph, with the only difference that IgG and IZ6I-vWF were incubated together for 15 min before addition to the other reagents. All IgG preparations were extensively dialyzed against the Tris buffer indicated above so that the ionic composition of the binding mixture was unchanged. The rest of the procedure was as described above.

RESULTS

Characterization of u WF Binding to Collagen-Preliminary experiments were performed to establish the optimal condi- tions for measuring vWF binding to collagen. The time course of the interaction demonstrated apparent equilibrium after 10 min of incubation, with minimal effect of varying the temper- ature between 4 and 37 "C (Fig. 1). Maximal binding was observed with pH between 6.5 and 7.5 and with NaCl concen- tration between 0.05 and 0.2 M in the buffer system described under "Materials and Methods." Excess unlabeled vWF in- hibited the binding of lZ5I-vWF when added at the same time and displaced the bound lZ5I-vWF when added after apparent equilibrium of binding had been reached (Fig. 2). These ex- periments established that the binding of vWF to collagen was saturable and reversible. Moreover, it was also found that the labeling procedure did not alter the affinity of the inter- action (Fig. 3). The amount of vWF bound varied as a function of the collagen concentration in the mixture. The latter was kept constant, as indicated under "Materials and Methods," a t a concentration selected to have a sufficient number of counts bound when 1251-vWF was used at concentrations up to 10 pg/ml. The relevant binding parameters for the vWF- collagen interaction were derived from Scatchard-type anal- ysis of binding isotherms, which suggested the existence of a single class of noninteracting binding sites (Fig. 4). The results of three such experiments are summarized in Table I.

The Effect of Monoclonal Antibodies on the Binding of u WF to Collagen-Twenty-one monoclonal antibodies directed against defined epitopes of vWF were tested for their ability to block the vWF-collagen interaction. Of these, 15 inhibited

zz0c

4 "C 37 "C

Incubation Time (Minutes) FIG. 1. Time course and temperature dependence of vWF

binding to collagen. The collagen concentration was 83 pglml, and the Iz5I-vWF was added at 2 pg/ml. After incubation for the time and at the temperature indicated for each curve, bound 1Z61-~WF was separated from free ligand by centrifugation of the insoluble collagen microfibrils through a layer of 20% sucrose. The tip of the microcen- trifuge tube containing the pelleted collagen and bound IZ6I-vWF was cut and counted in a y-scintillation spectrometer. The amount of vWF bound was calculated on the basis of its specific activity.

15312 uon Willebrand Factor-Collagen Interaction

YO Unlabeled vWF Added 100 80 60 40 20 0

I 1 I 0

" 0 1.56 6.25 25 100 400

Unlabeled vWF Added (pglml)

O b l b ;o 30 lo ;o $0 ;o Time After Addition of Unlabeled vWF

(Minutes) FIG. 2. Saturability and reversibility of vWF binding to

collagen. Top panel, in this experiment, unlabeled vWF (at the final concentrations indicated) was added to the tubes containing the collagen (83 pg/ml) at the same time as lZ5I-vWF (2 pg/ml). After incubation for 20 min at 22-25 "C, bound lZ5I-vWF was quantitated as indicated in the legend to Fig. 1. Lower panel, in this experiment, 'T-vWF (2 pg/ml) was incubated with collagen (83 pg/ml) for 15 min at 22-25 "C. At this point (indicated as time 0 on the abscissa) unlabeled vWF was added at a 100-fold excess (curue with open circles) or the same volume of Tris buffer was added as a control (curue with closed circles). The incubation was then continued for the time indicated and the lZ5I-vWF bound was quantitated as indicated in the legend to Fig. 1.

the binding of lZ5I-vWF to collagen, and six had no inhibitory effect (Fig. 5). The binding was actually increased in the presence of five of these antibodies (Fig. 5). All the inhibitory antibodies reacted with the 52/48-kDa tryptic fragment, whereas all the noninhibitory antibodies reacted with other fragments of the vWF subunit (see legend to Fig. 5). In particular, three antibodies (RG 51, RG 3, and RG 38) that reacted with a 55-kDa tryptic fragment corresponding to the middle region of the vWF subunit (see below) were among those showing no inhibitory effect. Three control monoclonal antibodies were also tested. Two were directed against distinct platelet membrane glycoproteins, GPIb and GPIIb. IIIa com- plex, and one was directed against thyroglobulin. They all showed no inhibitory effect.

The Effect of Proteolytic Fragments on the Binding of Intact u WF to Collagen-Three fractions containing the larger frag- ments derived from tryptic digestion of vWF (see also Ref. 25 for additional details) were tested for their inhibitory effect on the binding of intact vWF to collagen. This experiment was performed using the native preparations with intact di- sulfide bonds (Fig. 6). The fraction designated B completely blocked the binding, whereas fractions A and C had minimal or moderate inhibitory activity, respectively (Fig. 6).

The major component of fraction B had a molecular mass, under nonreducing conditions, of approximately 120 kDa (Fig. 6). After reduction of disulfide bonds, a closely spaced doublet of 52/48 kDa was seen in fraction B along with several other

1 2 0 1

a m" 80 c

u 2 6 0 1

/ I &? 401 20 '0 20 40 60 EO 100

I Labeled vWF Added FIG. 3. Relative binding of labeled and unlabeled vWF to

collagen. The total concentration of vWF was maintained constant in this experiment (2 pglml), but the relative proportions of labeled and unlabeled ligand varied, inversely, between 0 and 100% as indi- cated on the abscissa. After incubation for 20 min at 22-25 "C, the amount of radioactivity bound to the collagen was determined and expressed as a percentage of the value observed when only Iz5I-vWF was added to the mixture (100% binding). The line was fitted to the experimental points by linear regression analysis and gave a slope very close to the theoretical value of 1, expected when labeled and unlabeled ligand bind with the same affinity.

Bound lnMl

0 4 8 12

Added vWF (pglml) FIG. 4. Saturation curve of vWF binding to collagen. In-

creasing amounts of IZ5I-vWF, as indicated on the abscissa, were added to collagen (83 pg/ml) and incubated for 20 min at 22-25 "C. The amount of Iz5I-vWF bound to the collagen was then determined as indicated in the legend to Fig. 1. The values shown in this graph represent total binding. The inset shows a Scatchard-type plot of the experimental data obtained using the computer-assisted program LIGAND (33), and the points represent specific binding. The best fit for the experimental points was represented by a straight line sug- gesting the existence of a single class of noninteracting binding sites. The relevant binding parameters were, for this experiment: Iz5I-vWF bound at saturation = 5.68 pg/mg of collagen; K, = 7.76 X 10' M" (calculated per vWF subunit assuming a molecular mass of 275 kDa); nonsaturable (nonspecific) binding = 0.

smaller fragments. The 52/48-kDa doublet was purified to homogeneity and was found to inhibit completely the vWF- collagen interaction (Fig. 7). Other tryptic fragments of vWF, with molecular mass of 13, 22, 41, and 55 kDa, were also purified from fractions B and C under reducing and denatur- ing conditions and tested for their inhibitory activity. The effect of these other fragments was minimal at concentrations corresponding to those of the 52/48-kDa fragment that com- pletely inhibited vWF binding to collagen (Fig. 8). All the fragments, however, caused partial inhibition of binding when tested a t higher concentrations (Fig. 8). The NH2-terminal sequence of each of the purified polypeptides was determined

von Willebrand Factor-Collagen Interaction 15313 TABLE I

Relevant parameters of 1251-v WF binding to c o l k e n The binding parameters were obtained by Scatchard-type analysis

using the microcomputer program LIGAND (33). The values of KO are calculated per vWF subunit assuming a molecular mass of 275 kDa.

Exueriment '9 -vWF bound K"

MIW coNagen "1

1 5.68 7.76 X 10'

2 6.90 6.58 X 10'

A B C kDa 200- $3$ 116- 92- - 68-

45-

3 18.11 2.32 X 10'

vWF Fraction Added Monoclonal Antibody Added

FIG. 5. Effect of monoclonal antibodies on the binding of vWF to collagen. Purified IgG of each monoclonal antibody was tested at a final concentration of 0.5 mg/ml. 1251-vWF was a t a concentration of 2 pg/ml and collagen a t 83 pg/ml. The radiolabeled ligand and I& were incubated for 15 min before addition to the other components of the reaction mixture. This was followed by additional incubation for 20 min a t 22-25 "C. Binding is expressed as percent of that seen in a control mixture where Tris buffer was used instead of IgG. All antibodies identified by the letter K reacted against the 521 48-kDa fragment beginning at residue Val-449 of the vWF subunit. Moreover, RG 21, RG 42, and RG 46 reacted with the same fragment. RG 3, RG 38, and RG 51 reacted with the 55-kDa fragment beginning a t residue Asn-730, whereas RG 4 and RG 8 reacted with the 41-kDa fragment beginning a t residue Thr-1352. Antibody RG 7 reacted with cyanogen bromide fragment M 7, which begins a t residue Lys-185. The antibodies identified with black bars also inhibited the ristocetin- induced binding of vWF to platelets.

and located in the sequence of the vWF subunit. The 52/48- kDa doublet began a t residue Val-449, as already reported; the 13-kDa a t residue Gln-290; the 22-kDa at residue Val- 1927; the 41-kDa a t residue Thr-1352; and the 55-kDa a t residue Asn-730. The COOH terminus of the 52/48-kDa frag- ment corresponded to Lys-728. Altogether, these fragments represented over two-thirds of the mass of the vWF subunit.

The nature of the inhibitory effect of the 52/48-kDa frag- ment was evaluated in experiments where a constant amount of fragment was added to increasing amounts of intact I2'I-

vWF (Fig. 9). Analysis of the binding isotherms by a Scat- chard-type plot demonstrated that the affinity of binding was markedly decreased in the presence of the 52/48-kDa frag- ment, whereas the amount of vWF bound to collagen a t saturation was not decreased (Fig. 9). These results were confirmed in three separate experiments. Therefore, the frag- ment acted as a competitive inhibitor of vWF binding to collagen.

DISCUSSION

We have characterized a high affinity interaction between vWF and type I collagen that involves a discrete portion of the vWF subunit. The present studies have located this col-

FIG. 6. Effect of tryptic f r agmen t s of vWF on the binding of intact vWF to collagen. The concentration of '*'I-vWF was 2 pglml. The fractions indicated as A, B, and C were obtained by HPLC size exclusion chromatography of trypsin-digested vWF under non- denaturing conditions and were tested in their native form at the final concentration of 0.85, 1.47, 1.35 mg/ml, respectively. The lanes above each bar in the graph represent the pattern of the corresponding fraction on SDS-PAGE (5-15% linear gradient) under nonreducing conditions. The mobility of known molecular mass markers is indi- cated. All components of the reaction mixture were added together, and the incubation was for 20 min at 22-25 "C. Binding is expressed as percent of that seen in a control mixture where no competing fraction was added. Note the complete inhibition of binding observed with fraction B.

\ Added 52/48 kDa Fragment (pM)

FIG. 7. Inhibition of intact vWF binding to collagen by the purified 52/48-kDa tryptic f r agmen t of vWF. The experimental conditions are like those described in the legend to Fig. 6, except that purified 52/48-kDa fragment was used a t varying concentrations indicated on the abscissa. The inset shows the SDS-PAGE analysis of the purified, reduced, and S-carboxymethylated 52/48-kDa frag- ment. Binding is expressed as percent of that observed in the absence of competing fragment.

uon Willebrand Factor-Collagen Interaction

22kDa

1 vWF Tryptic Fragment Added

FIG. 8. Inhibition of intact vWF binding to collagen by four different purified tryptic fragments of vWF. The experimental conditions are like those described in the legend to Fig. 6. The fragments used are identified by their molecular mass, and their location in the sequence of the vWF subunit is reported under "Results." Binding is expressed as percent of that observed in the absence of competing fragment. The final concentrations used for each fragment are indicated. Note that the 52/48-kDa fragment inhibited binding greater than 90% at concentrations above 1 pM (see Fig. 7).

Added vWF (pglrnl) FIG. 9. Competitive inhibition of intact vWF binding to col-

lagen by the purified 52/48-kDa tryptic fragment of vWF. In this experiment, the binding of varying concentrations of '*'I-vWF to collagen was determined either in the absence (closed circles) or in the presence (open circles) of purified 52/48-kDa fragment (final concentration, 0.5 p ~ ) . The experimental conditions are as indicated in the legend to Fig. 4. The K, of the interaction (calculated per vWF subunit assuming a molecular mass of 275 kDa) was 6.52 X 10' M" in the absence of competing fragment and 1.36 X 10' M" in the presence of it. The amount of '251-vWF bound at saturation was 6.9

performed with the program LIGAND (33). Nonspecific binding was and 13.3 pg/mg, respectively, as calculated by Scatchard-type analysis

assumed to be 0 in both cases, as calculated for the curve in the absence of inhibitor.

lagen binding domain in a 52/48-kDa tryptic fragment that begins at amino acid residue Val-449 and extends through Lys-728 of the 2050 residues constituting the vWF subunit. This fragment retained the ability of completely inhibiting the binding of intact vWF to collagen when fully reduced and S-carboxymethylated, and 50% inhibition occurred at concen- trations between 0.3 and 0.5 PM. Thus, native conformation

is not required for expressing the binding function of this domain, at least when isolated from the vWF molecule.

Several lines of evidence indicate that the fragment we have identified is likely to represent the main vWF interaction site with the type I collagen used in these studies. Four other tryptic fragments located in the amino-terminal, middle, and carboxyl-terminal regions of the vWF subunit exhibited lim- ited inhibitory function and only at very high concentrations. At present, we cannot rule out the possibility that other collagen binding sites exist in the vWF subunit. Their func- tion might be more susceptible to the denaturing conditions employed for the purification of discrete portions of the vWF subunit and thus be less apparent than that of the 52/48-kDa fragment. Against this hypothesis, however, is the observation that only the fraction containing the 52/48-kDa polypeptide, of the three main fractions derived from a tryptic digest of vWF, exhibited a marked inhibitory effect on vWF binding to collagen even when tested under native conditions. It is also important to consider that the 52/48-kDa fragment acted as a competitive inhibitor of vWF binding to collagen, thus demonstrating that the intact molecule and the reduced and alkylated tryptic fragment interact with the same site on collagen.

Studies with monoclonal antibodies provide additional sup- port for the concept that the 52/48-kDa tryptic fragment represents the main vWF domain interacting with the type I collagen used in these studies. All antibodies directed against the 52/48-kDa polypeptide had an inhibitory effect on the vWF-collagen interaction, whereas none of those directed against other regions of the vWF subunit had any inhibitory effect. The observation that several antibodies not directed against the 52/48-kDa fragment actually increased the bind- ing of vWF to collagen may, in fact, indicate the existence of regulatory mechanisms which are mediated by other regions of the vWF subunit and result in decreased binding to colla- gen.

In previous studies (22, 34) other investigators have con- cluded that the epitope of a monoclonal antibody inhibiting vWF binding to collagen resided on a fragment of 48 kDa (unreduced) and 58 kDa after reduction and alkylation. This fragment corresponds to the one indicated as 55 kDa in the present study, isolated from fraction C (Fig. 6). We have tested three monoclonal antibodies reacting with this frag- ment and found that none of them inhibited the vWF-collagen interaction. The native fraction C, however, and the purified 55-kDa fragment had a partial inhibitory effect on vWF binding to collagen. It is possible, therefore, that a second collagen binding domain resides in this part of the vWF subunit, although its role appears secondary as compared to that of the domain in the 52/48-kDa fragment, at least under the experimental conditions used in the present work.

The collagen-vWF interaction, as characterized in these studies, is a rapid process and is temperature independent, saturable, reversible, and specific. Type I collagen appears to have a single class of binding sites that interact with a discrete domain of the vWF subunit with high affinity. Under the conditions employed in these experiments, therefore, the con- tribution of other putative binding sites to the vWF-collagen interaction was not apparent. While we have demonstrated that the multimeric structure of vWF is not required for the interaction, we have not addressed in this work the nature of the structural requirements of collagen for binding to occur. Although previous studies (18) suggest that collagen quater- nary structure, rather than collagen type per se, is the impor- tant factor determining vWF binding, additional work is necessary to elucidate at a molecular level the complex inter-

von Willebrand Factor-Collagen Interaction 15315

action of vWF with the different types of collagen. The 52/48-kDa tryptic fragment that contains the high

affinity collagen binding domain described here was previ- ously found by us to mediate the interaction of vWF with the platelet membrane receptor GPIb (25). In agreement with our findings, other investigators have provided indirect evidence, obtained with monoclonal antibodies, that the GPIb binding domain of vWF resides in the amino-terminal half of the molecule (22, 35). The immunoinhibition studies reported here indicate that these two functional domains, although residing in relative close proximity, are distinct from one another. Seven out of 15 antibodies directed against the 521 48-kDa fragment inhibited both binding activities of vWF, whereas the remaining eight blocked effectively the vWF- collagen interaction without affecting the one with GPIb. Additional experimental work will be necessary to define more precisely the structural basis for these functions of vWF.

Acknowledgments-We wish to express our gratitude to Dr. Koiti Titani for his supply of cyanogen bromide fragments of von Wille- brand factor; Dr. John McPherson for his help in analyzing the collagen preparations; James J. Roberts for his work in the prepara- tion of monoclonal antibodies; and Claire Jackson and Donna Boyer- Diorio for excellent secretarial assistance.

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

REFERENCES

Tschopp, T. B., Weiss, H. J., and Baumgartner, H. R. (1974) J.

Weiss, H. J., Turitto, V. T., and Baumgartner, H. R. (1978) J.

Weiss, H. J., Baumgartner, H. R., Tschopp, T. B., Turitto, V. T.,

Sakariassen, K. S., Bolhuis, P. A., and Sixma, J. J. (1979) Nature

Kao, K.-J., Pizzo, S. V., and McKee, P. (1979) J. Clin. Znuest.

Fujimoto, T., Ohara, S., and Hawiger, J . (1982) J. Clin. Znuest.

Ruggeri, Z. M., De Marco, L., Gatti, L., Bader, R., and Montgo-

Stel, H. V., Sakariassen, K. S., de Groot, P. G., VAN Mourik, J.

Turitto, V. T., Weiss, H. J., Zimmerman, T. S., and Sussman, I.

Bolhuis, P. A., Sakariassen, K. S., Sander, H. J., Bouma, B. N.,

Lab. Clin. Med. 83, 296-300

Lab. Clin. Med. 92, 750-764

and Cohen, D. (1978) Blood 51,267-279

279,636-638

63,656-664

69,1212-1222

mery, R. R. (1983) J. Clin. Inuest. 7 2 , 1-12

A., and Sixma, J. J. (1985) Blood 65,85-90

I. (1985) Blood 65,823-831

and Sixma, J. J. (1981) J. Lab. Clin. Med. 9 7 , 568-576 11. Sixma, J. J., Sakariassen, K. S., Beeser-Visser, N. H., Ottenhof-

Rovers, M., and Bolhuis, P. A. (1984) Blood 6 3 , 128-139 12. Nyman, D. (1977) Thromb. Res. 11 , 433-438 13. Legrand, Y. J., Rodriguez-Zeballos, A., Kartalis, G., Fauvel, F.,

14. Nyman, D. (1980) Thromb. Res. 17, 209-214 15. Santoro, S. A. (1981) Thromb. Res. 2 1 , 689-693 16. Scott, D. M., Griffin, B., Pepper, D. S., and Barnes, M. J . (1981)

17. Santoro, S. A., and Cowan, J. F. (1982) Collagen Relut. Res. 2 ,

18. Morton, L. F., Griffin, B., Pepper, D. S., and Barnes, M. J. (1983) Thromb. Res. 32,545-556

19. Kessler, C. M., Floyd, C. M., Rick, M. E., Krizek, D. M., Lee, S. L., and Gralnick, H. R. (1984) Blood 6 3 , 1291-1298

20. Houdijk, W. P. M., Sakariassen, K. S., Nievelstein, P. F. E. M., and Sixma, J. J. (1985) J. Clin. Znuest. 7 5 , 531-540

21. Wagner, D. D., Urban-Pickering, M., and Marder, V. J. (1984) Proc. Natl. Acad. Sci. U. S. A . 8 1 , 471-475

22. Sixma, J. J., Sakariassen, K. S., Stel, H. V., Houdijk, W. P. M., In der Maur, D. W., Hamer, R. J., de Groot, P. G., and Van Mourik, J . A. (1984) J. Clin. Inuest. 74, 736-744

23. Fressinaud, E., Sakariassen, K. S., Girma, J. P., Meyer, D., and Baumgartner, H. R. (1985) Blood 66, Suppl. 1,334a

24. Bockenstedt, P., Greenberg, J. M., and Handin, R. I. (1986) J. Clin. Inuest. 77, 743-749

25. Fujimura, Y., Titani, K., Holland, L. Z., Russell, S. R., Roberts, J. R., Elder, J. H., Ruggeri, Z. M., and Zimmerman, T. S. (1986) J. Biol. Chem. 261,381-385

26. Ruggeri, Z. M., Bader, R., and De Marco, L. (1982) Proc. Natl. Acad. Sci. U. S. A. 79,6038-6041

27. Fulcher, C. A., and Zimmerman, T. S. (1982) Proc. Natl. Acad. Sci. U. S. A. 79 , 1648-1652

28. Titani, K., Kumar, S., Takio, K., Ericsson, L. H., Wade, R. D., Ashida, K., Walsh, K. A., Chopek, M. W., Sadler, J. E., and Fujikawa, K. (1986) Biochemistry 25 , 3171-3184

29. Johnson, D. A., Gautsch, J. W., Sportsman, J. R., and Elder, J. H. (1984) Gene Anal. Techn. 1, 3-8

30. Bruck, C., Portetelle, D., Glineur, C., and Bollen, A. (1982) J. Immunol. Methods 53, 313-319

31. Scheele, G. A. (1975) J. Biol. Chem. 250, 5375-5385 32. Fraker, D. J., and Speck, J. C. (1978) Biochem. Biophys. Res.

33. Munson, P. J. (1983) Methods Enzymol. 92, 542-576 34. Houdijk, W. P. M., Schiphorst, M. E., and Sixma, J. J. (1986)

35. Girma, J.-P., Kalafatis, M., PiBtu, G., Lavergne, J.-M., Chopek, M. W., Edgington, T. S., and Meyer, D. (1986) Blood 67,1356- 1366

and Caen, J. P. (1978) Thromb. Res. 13,909-911

Thromb. Res. 24 , 467-472

31-43

Commun. 80,849-857

Blood 67,1498-1503